Hypertension in the OPD: The Evidence Behind the Pathway

A 44-year-old bank cashier from Mangaluru comes to the OPD for a fitness certificate. His blood pressure is 152/96 on the clinic machine. He is worried, because his father had a stroke at 60. At home, he says, his own machine reads “always normal”. The resident wants to start a tablet today and asks which one. This is an illustrative case, not a real patient.

The Hypertension OPD Pathway walks through his visit: whether this is hypertension, which target applies, which tablet to start, and when to step up. What the tool no longer carries is some of the why: the size of the problem in India, the disagreement between the Indian guidelines, and the trials behind each step. Those have moved here, so that the tool stays quick in a busy OPD. By the end you will know where each of the tool’s steps comes from.

1. Why this matters more in India

India carries the world’s largest absolute burden of hypertension. The ICMR-INDIAB study (2023) estimated that over 315 million Indians are hypertensive. Yet fewer than 1 in 10 have their blood pressure adequately controlled. Hypertension is the single largest contributor to cardiovascular death in India.

“Is the risk the same for our patients as for those in the Western trials?” It is higher. South Asians develop hypertension at a younger age. They carry more target organ damage per mmHg of elevation. The PURE study confirmed that they suffer cardiovascular events at a lower BP threshold. Early and aggressive guideline-directed treatment therefore matters more in this population, not less. That is why the tool asks you to screen every new patient for organ damage.

2. Where hypertension begins depends on which document is open

Three Indian guidelines are current, and they do not agree on the number at which a person becomes hypertensive. Take the patient at 134/86. That is Stage 1 hypertension to the Indian Society of Hypertension. To the national workflow and to IGH-V it is elevated blood pressure, and explicitly not hypertension. Whether that person is told they have a disease depends on which document is open.

Here are the three, side by side, as the tool carried them on 4 November 2026. The tool still shows every cell, as two narrower tables.

The common mistake is to argue about the label. The three disagree about the label more than about the destination. What reaches the prescription is the target, and the tool prints all three positions for the patient you enter.

3. Back to our cashier: is the clinic reading the truth?

His clinic reading is high and his home readings are normal. That is the pattern of white-coat hypertension. The opposite pattern, masked hypertension, is the more dangerous one, because it is so easily missed. Here is the table the tool uses, whole.

So the resident should not start a tablet today on one clinic reading. The tool’s practical tip applies: a validated upper-arm machine, readings twice a day for 7 days, days 2 to 7 averaged. A home average of 135/85 mmHg or more confirms hypertension. For patients, What is ABPM? explains the 24-hour test.

4. Resistant and refractory hypertension: how common?

“How many patients really need four or five drugs?” Fewer than you might think, once adherence and measurement are checked. Here is the tool’s table with its How common column, which now lives here.

5. The trials behind each step

The tool once listed seven landmark trials. It keeps one, ONTARGET, because its finding is a “do not”: dual RAS blockade increased renal events. The other six explain why the pathway looks the way it does. Each is in the reference list below.

Read the table against the tool. PATHWAY-2 is why spironolactone is step 3. ALLHAT is one reason a thiazide-like diuretic sits in the first combinations. SPRINT’s target of below 120 systolic is not one the tool applies.

Back to the OPD

Our cashier went home with a borrowed machine and a sheet for 7 days of readings. His home average came to 128/82. That is the pattern of white-coat hypertension. He was advised on salt and exercise, and asked to return in a year, or sooner if his home readings rose. His father’s stroke is a reason to keep checking, not a reason to treat a number that is not there.

Try this

A 58-year-old woman with type 2 diabetes reads 128/78 in the clinic. Her home readings over a week average 142/90. What is this pattern, and what does the tool advise? Illustrative case.

Answer. Masked hypertension: normal in the clinic, high at home. Its risk is similar to sustained hypertension, and it is often missed. It requires pharmacotherapy, confirmed by home monitoring or a 24-hour ABPM. With diabetes, her target is tighter as well.

Take-home points

• Over 315 million Indians are hypertensive, and fewer than 1 in 10 are controlled.
• The three Indian guidelines disagree on where hypertension begins; check the target, not just the label.
• Confirm a high clinic reading at home before starting a lifelong drug; look for masked hypertension too.
• Before calling hypertension resistant, check adherence, measurement and the drugs that raise BP.
• Never combine an ACE inhibitor with an ARB: dual RAS blockade increased renal events in ONTARGET.

For your patients: Doctor, Tell Me About High Blood Pressure.

Declaration: the author built and maintains the tool. It is free to use. The figures in this article are those the tool carried in its Evidence tab on 4 November 2026, with the sources as the tool named them. The illustrative case follows the tool’s rules; check the tool’s result for a real patient.

References

1. Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults. Hypertension. 2025. Published online 14 August 2025.
2. Mehta N, Mathur G, Pal J, Taneja A, Wander GS, et al. Indian Hypertension Guideline V (IGH-V), 2025-2026. Association of Physicians of India, with the Indian College of Physicians, the Cardiological Society of India and the Hypertension Society of India. J Assoc Physicians India. 2026;74(5).
3. Indian Council of Medical Research and Department of Health Research, Ministry of Health and Family Welfare, Government of India. Standard Treatment Workflow: Hypertension in Adults (ICD-11 BA00). New Delhi; May 2026.
4. Gupta R, Maheshwari A, Verma N, Narasingan SN, Tripathi K, Joshi S, Manoria PC. Indian Society of Hypertension (InSH) Consensus Guideline for the Management of Hypertension, 2025. Hypertension Journal. 2025;11(4):76-138.
5. McEvoy JW, et al. 2024 ESC Clinical Practice Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018.
6. Unger T, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334-1357.
7. Anjana RM, et al. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study. Lancet Diabetes Endocrinol. 2017;5(8):585-596.
8. Yusuf S, et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries (PURE Study). N Engl J Med. 2014;371(9):818-827.
9. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116.
10. ALLHAT Officers. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288(23):2981-2997.
11. Williams B, et al (PATHWAY-2). Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension. Lancet. 2015;386(10008):2059-2068.
12. Yusuf S, et al (ONTARGET). Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-1559.
13. HOPE Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-153.
14. National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD), Ministry of Health & Family Welfare, Government of India. Operational Guidelines: Prevention, Screening and Control of Common NCDs. 2023.